AI assistant
Sending…
Outlook Therapeutics, Inc. — Director's Dealing 2021
Apr 20, 2021
34620_dirs_2021-04-20_408221b5-faf6-4dd3-808d-906d5f85b279.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Outlook Therapeutics, Inc. (OTLK)
CIK: 0001649989
Period of Report: 2021-04-19
Reporting Person: Haddadin Yezan Munther (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-19 | Common Stock | P | 10000 | $1.82 | Acquired | 20000 | Direct |
More from Outlook Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
Jun 1
Proxy Solicitation & Information Statement
2026
Jun 1
Regulatory Filings
2026
Jun 1
Capital/Financing Update
2026
May 29
Share Issue/Capital Change
2026
May 29
Capital/Financing Update
2026
May 28
Regulatory Filings
2026
May 26
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Apr 23